Opinion

Video

Diagnosis and Prevalence of Demodex Blepharitis

Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis.

This is a video synopsis/summary of an Insights involving Neda Shamie, MD.

Until recently, there were no FDA-approved therapies for Demodex blepharitis. In the past, Demodexblepharitis was quite common but often left untreated for years. Various abrasive in-office procedures, home therapies encouraging patients to abrade their own eyelashes/eyelids, and chemical cleansers were tried to lessen the Demodexload, but none treated the root cause. These approaches often irritated patients more than the actual disease.

Demodexblepharitis is highly prevalent, with a recent study finding that 56% of cataract patients had pathognomonic signs, even without symptoms. Over 90% of patients intolerant of contact lenses and 60% of those on dry eye treatment had Demodex, indicating it is an underdiagnosed condition.

Diagnosing Demodexblepharitis is simple. The eye care specialist uses a slit lamp to look at the patient’s eyelash line. When the patient looks down, the doctor examines the eyelash base for collarettes, which are mite excretions that cluster and cake on the lashes. This can cause inflammation, hair follicle loss, and other issues.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo